Peripherally Inserted Central Catheters Market Size, Share, Growth, and Industry Analysis, By Type (Power Injected Peripherally Inserted Central Catheters,Conventional Peripherally Inserted Central Catheters), By Application (Hospitals,Ambulatory Surgical Centers,Catheterization Laboratories), Regional Insights and Forecast to 2035

Peripherally Inserted Central Catheters Market Overview

The global Peripherally Inserted Central Catheters Market size is projected to grow from USD 715.79 million in 2026 to USD 757.88 million in 2027, reaching USD 1196.55 million by 2035, expanding at a CAGR of 5.88% during the forecast period.

The Peripherally Inserted Central Catheters (PICC) Market focuses on long-term venous access devices inserted through peripheral veins and advanced to the central venous circulation. PICCs are essential for infusion therapy, chemotherapy, parenteral nutrition, and frequent blood sampling. Globally, more than 2.5 million patients undergo PICC insertion annually, with hospitals accounting for nearly 65 % of these procedures.

The United States remains the largest market, performing over 3 million PICC line insertions each year, representing more than 55 % of global adoption. Hospitals account for roughly 70 % of U.S. PICC placements, with oncology, infection management, and long-term antibiotic therapy being key applications.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~ 45 % of demand is fueled by increased cancer incidence and extended intravenous therapy usage.
• Major Market Restraint: ~ 25 % of market constraints are due to infection risk and procedural complications.
• Emerging Trends: ~ 30 % of new PICC launches feature antimicrobial coatings or pressure-rated designs.
• Regional Leadership: North America maintains approximately 40 % global share in PICC utilization.
• Competitive Landscape: The top five companies collectively hold around 52 % of global market share.
• Market Segmentation: Approximately 60 % of devices remain conventional, while 40 % are power-injectable.
• Recent Development: About 15 % of new products incorporate tip-locating and ECG placement systems.

Peripherally Inserted Central Catheters Market Latest Trends

Recent Peripherally Inserted Central Catheters Market Trends indicate substantial evolution in design, placement technology, and clinical application. The shift toward power-injectable catheters, now accounting for nearly 20 % of installations, supports contrast media administration for imaging while maintaining therapeutic access.

Peripherally Inserted Central Catheters Market Dynamics

The Peripherally Inserted Central Catheters Market Dynamics are defined by technological innovation, evolving patient care models, and a growing preference for long-term vascular access solutions. The market is experiencing significant structural change as demand shifts from inpatient to outpatient and home-care settings, now representing nearly 35 % of total global insertions. The rising prevalence of cancer, infectious diseases, and nutritional deficiencies has driven PICC utilization among more than 3.5 million patients worldwide each year.

DRIVER

"Rising demand for long-term intravenous therapy in oncology and chronic infection management."

Globally, over 3.5 million patients require peripherally inserted central catheters annually for extended drug delivery, parenteral nutrition, and chemotherapy. The need for sustained vascular access has surged by 25 % in the last five years, particularly in cancer care, infectious disease treatment, and nutrition management.

RESTRAINT

"Catheter-related bloodstream infections and procedural complications limit broader adoption."

Complications associated with PICCs, such as infection, thrombosis, and occlusion, impact approximately 5–8 % of total insertions globally. Catheter-related bloodstream infections occur in 1.5–3 % of cases, particularly in non-sterile or emergency insertions.

OPPORTUNITY

Expansion of home infusion services and adoption of antimicrobial PICCs in emerging markets.

The global expansion of home-based infusion therapy represents a major opportunity, expected to support 40 % of all long-term intravenous treatments by 2030. Increasing awareness of outpatient care efficiency and patient comfort has led to 12 % annual growth in home infusion adoption.

CHALLENGE

"Need for enhanced clinician training, tip-placement precision, and material durability."

Maintaining proper catheter placement remains a clinical challenge, as malposition occurs in 6–9 % of insertions globally. Operator expertise directly influences outcomes — over 70 % of placement errors occur during clinician training phases. Catheter fatigue or lumen rupture in extended dwell times exceeding 90 days affects roughly 3 % of patients, requiring premature device replacement.

Peripherally Inserted Central Catheters Market Segmentation

The Peripherally Inserted Central Catheters Market Segmentation is categorized by type and application, enabling detailed analysis of device usage across various clinical environments. By type, the market is divided into Power-Injected PICCs and Conventional PICCs.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Power-Injected Peripherally Inserted Central Catheters: Power-injectable PICCs account for nearly 35 % of the total market share, valued for their ability to withstand high-pressure injections up to 300 psi. These catheters are frequently used in radiology and oncology departments for combined drug delivery and diagnostic imaging procedures. Adoption rates exceed 40 % in North American hospitals and 25 % in European centers, supported by advanced healthcare infrastructure.

Power-injectable PICCs are projected to reach approximately USD 169.01 million in 2025, accounting for ~25.0 % of the global USD 676.04 million market, supported by clinical efficiency, high injection pressure tolerance, and advanced imaging compatibility, expanding steadily at 5.88 % CAGR during the forecast period.

Top 5 Major Dominant Countries in the Power-Injected PICC Segment

• United States: The U.S. market is estimated at ~USD 60 million, capturing ~35.5 % of the global segment share, driven by widespread hospital adoption, advanced vascular access systems, and increased usage in oncology and critical care procedures, growing near 5.6 % CAGR.
• Germany: Germany represents around ~USD 25 million, accounting for ~14.8 % of global share, led by a strong medical infrastructure, government-standardized infusion protocols, and technological advances in catheter materials and imaging, maintaining consistent growth close to 6.0 % CAGR.
• Japan: The Japanese market is valued near ~USD 20 million, holding ~11.8 % share, supported by strong adoption in tertiary hospitals, early adoption of precision-injection catheters, and procedural accuracy demand across complex patient management systems, expanding steadily at 5.9 % CAGR.
• China: China contributes approximately ~USD 15 million, or ~8.9 % of the total segment, with demand accelerating due to rapid hospital infrastructure expansion, increased oncology procedure volumes, and preference for high-performance vascular catheters, advancing at 6.2 % CAGR.
• United Kingdom: The United Kingdom accounts for nearly ~USD 12 million, securing ~7.1 % of market share, primarily supported by national healthcare investments, rapid PICC procedural standardization, and broader adoption across outpatient infusion centers, advancing steadily near 5.7 % CAGR.

Conventional Peripherally Inserted Central Catheters: Conventional PICCs remain dominant, holding approximately 65 % of global market share due to their lower cost and ease of use. These catheters are preferred in general hospitals, long-term care facilities, and home healthcare programs. Adoption in developing regions exceeds 80 %, where high-pressure injection capabilities are less essential.

Conventional Peripherally Inserted Central Catheters are projected to reach approximately USD 507.03 million in 2025, representing ~75.0 % of the global USD 676.04 million market, driven by their reliability, lower insertion complexity, and continued preference across hospitals and outpatient infusion settings, expanding at an average 5.88 % CAGR during the forecast timeline.

Top 5 Major Dominant Countries in the Conventional PICC Segment

• United States: The United States leads this segment with an estimated valuation of ~USD 200 million, accounting for ~39.5 % of the global market, supported by widespread clinical usage, standardized insertion protocols, and rising demand in chronic illness management, growing steadily at ~5.5 % CAGR.
• Germany: Germany’s conventional PICC market is valued near ~USD 80 million, comprising ~15.8 % of global share, bolstered by a strong hospital network, high per-capita healthcare expenditure, and rising preference for non-surgical catheter-based therapies, maintaining consistent expansion at ~5.9 % CAGR.
• Japan: Japan captures approximately ~USD 65 million, equating to ~12.8 % of the global segment share, attributed to its advanced healthcare infrastructure, strong adoption in intensive care units, and integration of infection-prevention technologies, expanding at a steady pace of ~5.8 % CAGR.
• China: China’s conventional PICC market stands at ~USD 55 million, securing ~10.8 % of global share, propelled by increasing hospital admissions, government-led healthcare reforms, and an accelerating focus on safe intravenous therapy, advancing robustly at ~6.1 % CAGR.
• France: France holds an estimated ~USD 40 million, representing ~7.9 % share of the global segment, driven by high patient safety standards, extensive use in oncology treatments, and adoption of advanced biocompatible catheter materials, progressing consistently at ~5.6 % CAGR.

BY APPLICATION

Hospitals: Hospitals represent the largest end-use segment, accounting for around 68 % of total PICC usage. Over 1.9 million hospital-based PICC insertions occur yearly, primarily across oncology, intensive care, and infectious disease departments. Hospitals favor power-injectable models in approximately 30 % of cases due to frequent diagnostic imaging.

The hospital segment dominates the global Peripherally Inserted Central Catheters (PICC) Market, valued at approximately USD 406.23 million in 2025, representing nearly ~60.0 % of total application share, driven by large patient volumes, integrated vascular access programs, and increasing PICC placements for oncology, antibiotic, and parenteral nutrition therapies.

Top 5 Major Dominant Countries in the Hospital Application

• United States: The U.S. hospital market is valued at around ~USD 150 million, contributing ~36.9 % of global share, supported by extensive hospital-based infusion centers, advanced vascular access protocols, and high utilization in chronic and critical care, expanding steadily at ~5.6 % CAGR.
• Germany: Germany accounts for approximately ~USD 60 million, securing ~14.8 % share, with strong procedural adoption in tertiary hospitals and oncology wards, aided by government investment in infection-prevention and vascular therapy technology, maintaining consistent expansion at ~5.9 % CAGR.
• Japan: Japan’s hospital market is projected at ~USD 50 million, equivalent to ~12.3 % of global share, driven by specialized infusion units, early adoption of power-injectable systems, and emphasis on clinical precision, progressing at ~5.8 % CAGR.
• China: China contributes nearly ~USD 45 million, accounting for ~11.1 % of total market share, fueled by rapid hospital infrastructure growth, increasing long-term therapy cases, and local manufacturing initiatives, growing steadily at ~6.1 % CAGR.
• France: France represents about ~USD 30 million, holding ~7.4 % share globally, backed by increasing hospital adoption for intensive and ambulatory care, advanced patient management systems, and strong clinician training initiatives, advancing at ~5.6 % CAGR.

Ambulatory Surgical Centers: Ambulatory surgical centers contribute nearly 20 % of global PICC insertions, driven by outpatient infusion therapy and reduced hospital stays. These centers perform an estimated 700,000 PICC placements annually, emphasizing patient comfort and shorter procedure times. Power-injectable devices are used in 25 % of cases, while conventional models dominate lower-acuity applications.

The Ambulatory Surgical Centers (ASCs) segment is projected at USD 169.01 million in 2025, representing ~25.0 % of the global Peripherally Inserted Central Catheters Market, supported by shorter inpatient stays, cost-efficient infusion therapies, and wider adoption of outpatient vascular access services.

Top 5 Major Dominant Countries in the ASC Application

• United States: The United States leads this segment with an estimated ~USD 65 million, representing ~38.4 % share globally, driven by rising outpatient infusion procedures, oncology day-care expansion, and focus on patient comfort, increasing steadily at ~5.6 % CAGR.
• Germany: Germany’s ASC market stands at around ~USD 27 million, equating to ~16.0 % share, supported by strong regulatory frameworks, reimbursement flexibility, and procedural efficiency in vascular care centers, growing consistently at ~5.9 % CAGR.
• Japan: Japan contributes approximately ~USD 22 million, representing ~13.0 % share, supported by hospital-ASC integration models, faster patient turnaround times, and technological upgrades improving catheter placement success, advancing near ~5.8 % CAGR.
• China: China holds nearly ~USD 18 million, accounting for ~10.7 % global share, benefiting from private ASC proliferation, increased healthcare accessibility, and targeted expansion of outpatient IV therapy centers, maintaining growth at ~6.1 % CAGR.
• United Kingdom: The U.K. ASC market is estimated at ~USD 12 million, capturing ~7.1 % share, driven by clinical efficiency reforms, demand for non-hospital care, and adoption of modern vascular access devices, expanding steadily at ~5.6 % CAGR.

Catheterization Laboratories: Catheterization laboratories and interventional radiology units account for approximately 12 % of total usage. Around 300,000 PICCs are deployed annually for diagnostic and interventional procedures requiring temporary vascular access. Power-injectable catheters are preferred for their dual utility in imaging and therapy.

The Catheterization Laboratories (Cath Labs) segment is forecasted to reach USD 100.81 million in 2025, accounting for approximately ~15.0 % of total global share, supported by growing cardiovascular and interventional procedures requiring central line access and continuous hemodynamic monitoring.

Top 5 Major Dominant Countries in the Catheterization Laboratory Application

• United States: The U.S. Cath Lab segment is valued at ~USD 35 million, representing ~34.7 % global share, propelled by high interventional cardiology procedure volumes, strong hospital integration, and adoption of advanced power-injectable catheters, rising near ~5.6 % CAGR.
• Germany: Germany’s Cath Lab market contributes around ~USD 15 million, holding ~14.9 % share, driven by increased angiographic procedures, interventional radiology expansion, and favorable clinical training for vascular access, maintaining growth close to ~5.9 % CAGR.
• Japan: Japan represents approximately ~USD 13 million, or ~12.9 % share, supported by rapid innovation in minimally invasive therapy and high cardiovascular disease prevalence, fostering sustained growth at ~5.8 % CAGR.
• China: China’s Cath Lab market size stands near ~USD 12 million, capturing ~11.9 % global share, boosted by government healthcare investment, growing interventional cardiac units, and physician training programs, advancing steadily at ~6.1 % CAGR.
• France: France holds about ~USD 8 million, equivalent to ~8.0 % of global share, fueled by advanced imaging systems integration and clinical use of biocompatible PICC materials, ensuring consistent expansion at ~5.6 % CAGR.

Regional Outlook for the Peripherally Inserted Central Catheters Market

The Peripherally Inserted Central Catheters Market Regional Outlook reveals strong geographic differentiation shaped by infrastructure maturity, healthcare spending, and procedural preferences. North America leads the global landscape with approximately 38 % of total market share, supported by widespread usage across hospitals, ambulatory centers, and home infusion programs. The United States alone performs more than 3 million annual PICC insertions, reflecting its dominance in both innovation and procedural volume.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds nearly 38 % of the global Peripherally Inserted Central Catheters Market Size, supported by widespread adoption across hospitals, ambulatory centers, and home infusion networks. The United States alone accounts for over 3 million annual insertions, representing 85 % of regional procedures. Canada contributes 8 %, while Mexico makes up 5 %, with consistent growth driven by infrastructure upgrades.

In 2025, the North American Peripherally Inserted Central Catheters (PICC) Market is projected to reach approximately USD 262.82 million, holding nearly ~38.9 % of global market share, supported by advanced healthcare infrastructure, high procedural accuracy, and growing integration of power-injectable and antimicrobial-coated catheter systems across hospitals and outpatient infusion centers.

North America – Major Dominant Countries in the “Peripherally Inserted Central Catheters Market”

• United States: The United States dominates with an estimated ~USD 225 million, accounting for ~85.6 % of the regional share, driven by large-scale clinical utilization, rising chronic illness cases, and growing adoption of digitally guided insertion systems, maintaining strong market leadership with steady expansion near ~5.7 % CAGR.
• Canada: Canada represents approximately ~USD 20 million, equating to ~7.6 % of the regional market, with growth attributed to its well-regulated healthcare system, increased adoption of outpatient infusion therapies, and rising use of antimicrobial PICCs across tertiary hospitals, advancing near ~5.8 % CAGR.
• Mexico: Mexico contributes around ~USD 12 million, securing ~4.6 % share regionally, supported by healthcare modernization programs, the expansion of private infusion centers, and gradual transition to power-injectable catheter systems, progressing steadily at ~6.0 % CAGR.
• Brazil (trade link): Brazil accounts for ~USD 3 million, capturing ~1.1 % of the regional share, benefiting from increasing medical tourism and adoption of minimally invasive vascular procedures, growing at a consistent ~5.9 % CAGR.
• Argentina (trade link): Argentina holds ~USD 2 million, representing ~0.8 % of North America’s linked trade share, with market expansion driven by cross-border device importation and increased procedural training adoption, rising steadily at ~5.8 % CAGR.

EUROPE

Europe captures approximately 28 % of the global market, driven by increasing use in oncology and geriatric care. Germany, France, and the UK collectively account for 60 % of European demand, with over 1 million PICC insertions annually. Adoption of power-injectable devices in advanced imaging departments exceeds 35 %, while antimicrobial variants represent 22 % of total usage.

The European Peripherally Inserted Central Catheters (PICC) Market is expected to reach approximately USD 169.01 million in 2025, capturing around ~25.0 % of global share, propelled by the high adoption rate of advanced vascular access devices, integration of imaging-assisted placement systems, and expanding use in oncology and critical care units across the region.

Europe – Major Dominant Countries in the “Peripherally Inserted Central Catheters Market”

• Germany: Germany leads with an estimated ~USD 60 million, accounting for ~35.5 % of the regional share, driven by government-supported medical technology innovation, robust hospital infrastructure, and strong procedural standardization, sustaining healthy growth at ~5.9 % CAGR.
• United Kingdom: The United Kingdom follows with ~USD 30 million, capturing ~17.8 % regional share, propelled by NHS-backed infusion therapy programs, advanced training protocols for catheter placement, and increased preference for power-injectable systems, maintaining steady expansion at ~5.7 % CAGR.
• France: France contributes approximately ~USD 25 million, holding ~14.8 % share of Europe’s market, with demand fueled by oncology and chronic care infusion therapies, and increasing hospital investments in antimicrobial catheter coatings, progressing consistently near ~5.8 % CAGR.
• Italy: Italy’s market stands at ~USD 20 million, securing ~11.8 % regional share, supported by national healthcare digitization initiatives and expanded usage in post-surgical intravenous therapy, demonstrating sustained growth at ~5.7 % CAGR.
• Spain: Spain represents around ~USD 15 million, or ~8.9 % of the regional share, benefiting from healthcare decentralization policies, increased private-sector hospital investments, and enhanced clinician training in catheterization procedures, expanding steadily at ~5.8 % CAGR.

ASIA-PACIFIC

Asia-Pacific represents nearly 25 % of global share, driven by rapid expansion of healthcare infrastructure and higher chronic disease prevalence. China and India collectively perform more than 1.2 million PICC procedures each year, contributing 65 % of regional volume. Japan and South Korea lead in technology integration, with 30 % of facilities using ECG-guided insertion systems.

The Asia-Pacific Peripherally Inserted Central Catheters Market is valued at approximately USD 169.01 million in 2025, accounting for ~25.0 % of the global market, driven by rapid healthcare infrastructure development, increased hospital procedural volumes, and government efforts to expand intravenous therapy access across emerging economies.

Asia-Pacific – Major Dominant Countries in the “Peripherally Inserted Central Catheters Market”

• China: China leads the Asia-Pacific region with ~USD 60 million, representing ~35.5 % of the regional share, fueled by increasing hospital capacity, expanded manufacturing of domestic catheters, and aggressive adoption of digital-guided insertion systems, rising steadily near ~6.0 % CAGR.
• Japan: Japan follows with approximately ~USD 35 million, equating to ~20.7 % share, driven by high healthcare standards, integration of advanced imaging in vascular access, and rising chronic illness burden requiring continuous infusion, advancing consistently at ~5.9 % CAGR.
• South Korea: South Korea’s market is valued near ~USD 20 million, or ~11.8 % share, supported by investment in hybrid catheter technologies, government-led innovation programs, and a growing patient base requiring long-term therapy, progressing steadily around ~6.0 % CAGR.
• India: India accounts for about ~USD 18 million, representing ~10.7 % share, with strong market growth attributed to improving hospital infrastructure, increasing affordability of PICCs, and expansion of infusion therapy centers, advancing at ~6.2 % CAGR.
• Singapore: Singapore contributes roughly ~USD 8 million, capturing ~4.7 % of regional share, bolstered by its role as a medical hub for Southeast Asia and adoption of advanced catheterization systems, maintaining expansion close to ~5.8 % CAGR.

MIDDLE EAST & AFRICA

The Middle East & Africa region holds about 9 % of global share, supported by rising healthcare investment and medical tourism. The United Arab Emirates and Saudi Arabia account for 55 % of regional procedures, followed by South Africa and Egypt. Annual PICC placements exceed 400,000, with infection-resistant and valved models gaining traction in tertiary hospitals.

The Middle East & Africa (MEA) Peripherally Inserted Central Catheters Market is projected at USD 75.19 million in 2025, accounting for ~11.1 % of global market share, driven by growing healthcare infrastructure, rising investments in tertiary care centers, and increasing awareness of advanced vascular access technologies across hospitals in the region. The adoption of power-injectable and antimicrobial PICCs is rising in the Gulf states and South Africa, supported by public health modernization programs and expanding medical imports.

Middle East & Africa – Major Dominant Countries in the “Peripherally Inserted Central Catheters Market”

• United Arab Emirates: The UAE market is valued at ~USD 25 million, representing ~33.3 % of the regional share, driven by strong healthcare investments, hospital accreditation programs, and rapid adoption of power-injectable catheters, expanding at ~5.9 % CAGR.
• Saudi Arabia: Saudi Arabia follows with approximately ~USD 18 million, contributing ~24.0 % of the regional share, propelled by large-scale hospital projects, increased chronic care units, and domestic distribution growth for vascular devices, sustaining consistent growth near ~6.0 % CAGR.
• South Africa: South Africa’s market stands at ~USD 12 million, equivalent to ~16.0 % of the regional share, fueled by expanding medical device access, public-private partnerships, and adoption in specialized oncology units, maintaining steady progress at ~5.9 % CAGR.
• Egypt: Egypt represents around ~USD 10 million, capturing ~13.3 % share regionally, with increased procurement of imported catheters and government-supported hospital modernization programs, expanding consistently at ~5.8 % CAGR.
• Nigeria: Nigeria’s market is valued at ~USD 5 million, accounting for ~6.7 % of the MEA market, supported by healthcare digitization, urban hospital expansion, and growing international supply partnerships, progressing steadily near ~6.1 % CAGR.

List of Top Peripherally Inserted Central Catheters Companies

• Vygon
• Braun Melsungen AG
• R. Bard
• Teleflex
• Cook Medical
• Theragenics
• AngioDynamics
• Medtronic
• Argon Medical

Vygon: Vygon leads the market with over 22 % global share, offering an extensive portfolio of single, double, and triple-lumen PICCs across 90 countries. The company’s Powerline® range is used in more than 1 million procedures annually worldwide.

1. Braun Melsungen AG: Holding roughly 18 % global share, B. Braun provides advanced PICCs featuring antimicrobial coatings and closed-system valves. Its global distribution spans over 70 nations, serving both acute and home care facilities.

Investment Analysis and Opportunities

The Peripherally Inserted Central Catheters Market Investment Outlook highlights strong growth potential across home infusion, outpatient therapy, and emerging healthcare economies. Investment in R&D exceeds USD 400 million annually, with over 60 % directed toward developing antimicrobial coatings, biocompatible polymers, and pressure-rated designs. Manufacturers focusing on cost-effective production for Asia and Latin America are capturing significant mid-tier demand. Strategic mergers and partnerships are rising by 15 % per year, aiming to consolidate regional distribution networks and strengthen clinical training programs.

New Product Development

Innovation within the Peripherally Inserted Central Catheters Market Trends centers on improving patient safety, reducing infection risk, and extending device longevity. Over 25 % of recent launches incorporate antimicrobial or heparin-bonded surfaces, cutting bloodstream infection incidence by nearly 30 %. Power-injectable variants, capable of withstanding injection pressures of 300 psi, have expanded clinical utility in imaging and oncology. ECG-guided placement technology has reduced malposition rates by 20 %, while newer materials, such as thermoplastic elastomers, extend average dwell time by 15 %.

Five Recent Developments

• Advanced ECG-guided and ultrasound-based PICC insertion systems improved placement precision by 25 %, reducing malposition and procedural complications globally.
• Internal valve and closed-end PICC designs reduced reflux and occlusion incidents by 20 %, enhancing safety and procedural efficiency worldwide.
• Multi-lumen power-injectable PICCs with 300 psi capacity increased by 28 %, supporting simultaneous infusions and diagnostic imaging efficiency.
• Antimicrobial and heparin-bonded coatings adoption rose 40 %, lowering bloodstream infection rates by 35 % in long-term vascular access cases.
• Smart digitally connected PICCs featuring integrated sensors and wireless data tracking increased 15 %, enabling real-time flow and pressure monitoring globally.

Report Coverage of Peripherally Inserted Central Catheters Market

The Peripherally Inserted Central Catheters Market Report provides in-depth coverage of product types, applications, and regional performance from 2025–2034. The report examines both power-injectable and conventional PICCs, analyzing clinical applications across hospitals, ambulatory surgical centers, and catheterization laboratories. Detailed regional assessments cover North America, Europe, Asia-Pacific, and the Middle East & Africa, supported by quantitative data on procedural volume, technology penetration, and adoption rates.

Peripherally Inserted Central Catheters Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 715.79 Million in 2026
Market Size Value By	USD 1196.55 Million by 2035
Growth Rate	CAGR of 5.88% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Power Injected Peripherally Inserted Central Catheters Conventional Peripherally Inserted Central Catheters By Application : Hospitals Ambulatory Surgical Centers Catheterization Laboratories
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample